A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden
A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden
复制标题
DOI：
10.1111/j.1600-0420.2005.00560.x
复制
发表时间：
2006-02-01
期刊：
影响因子：
--
通讯作者：
Evans, SJ
中科院分区：
文献类型：
--
作者：
Lindblom, B;Nordmann, JP;Evans, SJ
目的：评估资源利用和成本与青光眼管理在法国和瑞典。方法：共267例患者的记录（121在法国，146在瑞典）诊断原发性开角型青光眼（POAG）和高眼压症（OH），治疗药物，进行了审查，为2年的时间（1997-99年期间开始）相关的临床和资源利用数据。经济数据被应用到估计治疗costs.Results：治疗青光眼的年成本估计为瑞典克朗5305（EURO 531）/例在瑞典和EURO 390/例在法国。在这两个国家，药物费用约占总费用的一半。外科手术和住院治疗的总成本在法国（7.0%和9.6%，分别）比在瑞典（3.7%和0.6%，分别）。结论：药物治疗费用占总治疗费用的比例很高。这些发现强调了药物治疗和评估青光眼药物成本效益的相对重要性。
Purpose: To assess resource utilization and costs associated with glaucoma management in France and Sweden.Methods: A total of 267 patient records (121 in France, 146 in Sweden) with diagnoses of primary open-angle glaucoma (POAG) and ocular hypertension (OH), treated medically, were reviewed for a 2-year period (beginning during 1997-99) for relevant clinical and resource utilization data. Economic data were applied to estimate treatment costs.Results: The annual cost of treating glaucoma was estimated at SEK5305 (EURO531)/patient in Sweden and EURO390/patient in France. In both countries, medication costs comprised about half of the total costs. Surgical procedures and hospitalizations represented greater proportions of total cost in France (7.0% and 9.6%, respectively) than in Sweden (3.7% and 0.6%, respectively).Conclusion: Medication costs represent a high proportion of total treatment costs. These findings highlight the relative importance of medical therapy and of assessing the cost-effectiveness of medications in glaucoma.